Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2054 • ACR Convergence 2022
Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
Kathryn Connelly¹, Laura Eades², Rachel Koelmeyer³, Darshini Ayton³, Vera Golder², Rangi Kandane-Rathnayake², Kate Gregory-Wong³, Hussein Al-Mossawi⁴, Jeanette Andersen⁵, Cynthia Aranow⁶, Laurent Arnaud⁷, Anca Askanase⁸, Subhashis Banerjee⁹, Catherine Barbey¹⁰, Hermine Brunner¹¹, Joy Buie¹², Laurie Burke¹³, Alain Cornet¹⁴, Karen Costenbader¹⁵, Maria Dall'Era¹⁶, Khadija Dantata¹⁷, Nikolay Delev⁹, Ann Eldred¹⁸, Alan Friedman¹⁹, Richard Furie²⁰, Sandra Garces²¹, Dennis Grasela²², Heath Guay²³, Oliver Guenther²⁴, Maria Juarez²⁵, Shelly Kafka²⁶, Kenneth Kalunian²⁷, Elaine Karis²⁸, Youmna Lahoud²⁹, Catharina Lindholm³⁰, Jeffrey Lockman³¹, Charlotte Lupton³², Justine Maller³³, Ashley Marion³⁴, Patrick Marquis³⁵, Joan Merrill³⁶, Thomas Morel³⁷, Marta Mosca³⁸, Yulia Pincus³⁹, Samantha Pomponi⁴⁰, Guillermo Pons-Estel⁴¹, Jorge Ross Terres³³, Cailin Sibley⁴², Maria Silk⁴³, Sanjeev Roy⁴⁴, Lee S Simon⁴⁵, Alessandro Sorrentino⁴⁶, Christian Stach⁴⁷, George Stojan⁴⁸, Ying Sun²⁴, Yoshiya Tanaka⁴⁹, Erik Thomas⁵⁰, Ronald van Vollenhoven⁵¹, Cristina Vazquez Mateo⁵⁰, Edward M Vital⁵², Victoria Werth⁵³, Eric Zollars²⁸, Qing Zuraw⁵⁴ and Eric Morand⁵⁵, ¹Monash Health, Camberwell, Australia, ²Monash University, Clayton, Australia, ³Monash University, Melbourne, Australia, ⁴AstraZeneca, Bucks, United Kingdom, ⁵Lupus Europe, Lupus DK, EULAR PARE, ERN ReCONNECT, Brussels, Belgium, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France, ⁸Columbia University Medical Center, New York, NY, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Biogen, Baar, Switzerland, ¹¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ¹²Lupus Foundation of America, Charleston, SC, ¹³LORA Group, Royal Oak, MD, ¹⁴Lupus Europe, Brussels, Belgium, ¹⁵Brigham and Women's Hospital, Boston, MA, ¹⁶University of California, Division of Rheumatology, San Francisco, CA, ¹⁷Lupus Foundation of America, Richmond Hill, GA, ¹⁸AbbVie, Inc., Lake Bluff, IL, ¹⁹AbbVie, Inc., Libertyville, IL, ²⁰Northwell Health, Great Neck, NY, ²¹Amgen, Inc., Almada, Portugal, ²²Bristol Myers Squibb, Lawrencevile, NJ, ²³AbbVie, Inc., Worcester, MA, ²⁴Merck KGaA, Darmstadt, Germany, ²⁵UCB Pharma, Slough, United Kingdom, ²⁶AbbVie, Inc., Norristown, PA, ²⁷University of California San Diego, La Jolla, CA, ²⁸Amgen, Inc., Thousand Oaks, CA, ²⁹Biogen International GmbH, Milton, MA, ³⁰AstraZeneca, Gothenburg, Sweden, ³¹Bristol-Myers Squibb, New York, NY, ³²AstraZeneca, Cambridge, United Kingdom, ³³Genentech, San Francisco, CA, ³⁴Lupus Foundation of America, Washington, DC, ³⁵Modus Outcomes, Cambridge, MA, ³⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ³⁷UCB Pharma, Brussels, Belgium, ³⁸University of Pisa, Pisa, Italy, ³⁹Janssen, Flemington, NJ, ⁴⁰Bristol Myers Squibb, Lawrence Township, NJ, ⁴¹Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ⁴²Janssen Research & Development, San Diego, CA, ⁴³Eli Lilly, Carmel, IN, ⁴⁴Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany,⁴⁵SDG LLC, West Newton, MA,⁴⁶AstraZeneca, Sollentuna, Sweden, ⁴⁷UCB Pharma, Monheim, ⁴⁸UCB Pharma, Baltimore, MD, ⁴⁹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁵⁰EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ⁵¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵³University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁵⁴Janssen Research and Development, LLC, Spring House, PA, ⁵⁵Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Most late-phase randomised controlled trials (RCTs) of novel drugs for systemic lupus erythematosus (SLE) have failed to meet their primary endpoint or shown contradictory…
Abstract Number: 2071 • ACR Convergence 2022
The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), American College of Rheumatology (ACR), and Lupus Foundation of America (LFA) Damage Index Revision – Item Generation Phase
Burak Kundakci¹, Megan R W Barber², Ann E Clarke², Sindhu R. Johnson³, Hermine Brunner⁴, Jiacai Cho⁵, Nathalie Costedoat-Chalumeau⁶, Ellen M. Ginzler⁷, John Hanly⁸, Abida Hasan⁷, Murat İnanç⁹, Naureen Kabani⁷, Alexandra Legge¹⁰, Kaitlin Lima¹¹, Livia Lindoso¹², Anselm Mak¹³, Rosalind Ramsey-Goldman¹¹, Guillermo Ruiz-Irastorza¹⁴, Clovis A. Silva¹², Farah Tamirou¹⁵, Vitor C. Trindade¹², Evelyne Vinet¹⁶ and Ian N. Bruce¹, ¹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ²University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ⁵National University Health System (NUHS), Singapore, Singapore, ⁶Inserm DR Paris 5, Paris, France, ⁷SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ⁸Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, ⁹Istanbul University Faculty of Medicine, Istanbul, Turkey, ¹⁰Arthritis Research Canada, Dalhousie University, Halifax, NS, Canada, ¹¹Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ¹²Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil, ¹³Division of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ¹⁴Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, ¹⁵Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁶McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: The SLICC, ACR and LFA embarked on a data- and expert-driven project to develop a revised systemic lupus erythematosus (SLE) organ damage index (SDI).…
Abstract Number: 2088 • ACR Convergence 2022
Achieving Systemic Lupus Erythematosus Disease Control or Low Lupus Disease Activity State Is Associated with Lower Rates of Organ Damage: Results from the Hopkins Lupus Cohort
Jacob N. Hunnicutt¹, Mary E. Georgiou², Anna Richards², Holly Quasny³, Laurence S Magder⁴, Daniel W. Goldman⁵ and Michelle Petri⁵, ¹GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, ²GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ³GlaxoSmithKline, Clinical Sciences, Research Triangle Park, NC, ⁴University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: The treatment target for systemic lupus erythematosus (SLE) is remission or, if this cannot be reached, the lowest disease activity achievable with the least…
Abstract Number: 2183 • ACR Convergence 2022
mTORC2 Contributes to Murine Systemic Autoimmunity
Xian Zhou¹, Haiyu Qi¹, Meilu Li¹, Yanfeng Li¹, Xingxing Zhu², Anne Davidson³ and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: The development of many systemic autoimmune diseases, including systemic lupus erythematosus, is associated with overactivation of the type I interferon (IFN) pathway, lymphopenia, and…
Abstract Number: 0098 • ACR Convergence 2022
Delays in Access to Specialized Care and Diagnosis in Patients with Systemic Lupus Erythematosus
Alain Sanchez-Rodriguez¹, Jose A Meade-Aguilar², Jeffrey X. Yang², Gabriel Figueroa Parra², Shirley-Ann Osei-Onomah², Rachel Giblon³, Hannah Langenfeld⁴, Alanna Chamberlain², Cynthia Crowson⁵ and Ali Duarte-Garcia², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Delays in access to specialized care and diagnosis of systemic lupus erythematosus (SLE) are associated with poor outcomes. Prior studies rely mostly on cross-sectional…
Abstract Number: 0319 • ACR Convergence 2022
Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy
Daming Shao¹, Alejandra Londoño Jimenez², Maria Auxiliadora Salgado Guerrero³, Anna Broder⁴ and Shudan Wang⁵, ¹Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²McFarland Clinic, Ames, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hackensack University Medical Center, Hackensack, NJ, ⁵Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Approximately 10 to 30% of patients with LN progress…
Abstract Number: 0337 • ACR Convergence 2022
Expanded Autoantibody Profiling in Incomplete Lupus Erythematosus
Rebecca Wood¹, Catriona Wagner², Carla J. Guthridge³, Joel Guthridge³, Steve Wallace⁴, Pennina R Safer⁵ and Judith James³, ¹Oklahoma Medical Research Foundation, Edmond, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Immunarray, Richmond, ⁵Immunarray, Rehovot, Israel
Background/Purpose: Incomplete lupus erythematosus (ILE) involves clinical and/or serologic manifestations consistent with but insufficient for SLE classification. While a subset of ILE patients transition to…
Abstract Number: 0354 • ACR Convergence 2022
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States
Sandra Sze-jung Wu¹, Allison Perry², Helen Varker³, Rich Bizier³, Liisa Palmer³ and Gary Bryant⁴, ¹AstraZeneca, Hockessin, DE, ²IBM Watson Health, New York, NY, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease associated with periods of flares. Identifying patients at risk of severe disease and associated resource…
Abstract Number: 0538 • ACR Convergence 2022
Contemporary Incidence of Lupus Nephritis Among Patients with Systemic Lupus Erythematosus in the United States
April Jorge¹, Baijun Zhou¹, Jacquelyn Nestor¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Lupus nephritis is a leading cause of morbidity in patients with systemic lupus erythematosus (SLE). We sought to determine the incidence of lupus nephritis…
Abstract Number: 0641 • ACR Convergence 2022
IL-4 Receptor Signaling and IKAROS Transcriptomic Program Maintains Naïve B-cell Quiescence and Antagonizes SLE
John Mountz, Min Gao, Shanrun Lui, Walter Chatham and Hui-Chen Hsu, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Factors that promote B-cell quiescence and homeostasis at the transitional (Tr) and naive stages of B cells to prevent excessive TLR7 and type I…
Abstract Number: 0661 • ACR Convergence 2022
Cutaneous Type I IFN Responses in Systemic Lupus Erythematosus Are Associated with Inflammatory Phenotype and Altered Wound Healing Function of Lupus Fibroblasts from Non-Lesional Skin
Lisa Abernathy-Close, Suzanne Shoffner-Beck, Annie Lu, Amanda Victory, Amy Hurst, Craig Dobry, Rachael Wasikowski, Johann Gudjonsson, Alex Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogenous, disfiguring, and difficult-to-treat manifestation of systemic lupus erythematosus (SLE) with scar formation in CLE subtypes such as…
Abstract Number: 0819 • ACR Convergence 2022
Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center
Anchal Sabharwal¹, Yuanqing Liu¹, Yazmin Rustomji¹ and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: Connective tissue diseases (CTDs) are a category of autoimmune disease in which interstitial lung disease (ILD) is a common pulmonary manifestation. Due to the…
Abstract Number: 0965 • ACR Convergence 2022
Pregnancy Outcomes in a Diverse Lupus Cohort
Julia Simard¹, Emily Liu², Eliza Chakravarty³, Amadeia Rector¹, Miranda Cantu⁴, Daniel Kuo⁵, Gary Shaw⁶, Maurice Druzin⁶, Michael Weisman⁷ and Monique Hedderson², ¹Stanford University School of Medicine, Palo Alto, CA, ²Kaiser Permanente Northern California’s Division of Research, Oakland, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Global Lupus Support Group, Portage, MI, ⁵Kaiser Permanente, Redwood City Medical Center, Redwood City, CA, ⁶Stanford University School of Medicine, Palo Alto, ⁷Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although the overall systemic lupus (SLE) patient population is racially and ethnically diverse, many study populations are homogeneous. We assembled a diverse group of…
Abstract Number: 0987 • ACR Convergence 2022
A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
Stacey Dillon¹, Pille Harrison², Jason Lickliter³, Kristi Manjarrez¹, Alina Smith¹, Mary Lessig¹, Lori Blanchfield¹, Russell Sanderson¹, Allison Chunyk¹, Tiffany Blair¹, Amanda Enstrom¹, Martin Wolfson¹, Mark Rixon¹, Hany Zayed⁴, Rupert Davies¹ and Stanford Peng¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Taunton, United Kingdom, ³Nucleus Network, Melbourne, Australia, ⁴Alpine Immune Sciences, San Francisco, CA
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are tumor necrosis factor (TNF) superfamily members that bind TACI (transmembrane activator and CAML…
Abstract Number: 1003 • ACR Convergence 2022
Does LLDAS Definition Match the Rheumatologist Opinion? The First Visit Evaluation of a Longinudital Spanish Multicenter Study to Assess Reasons of Disagreement
Coral Mouriño Rodriguez¹, Irene Altabas Gonzalez¹, Iñigo Rúa-Figueroa², Norman Jimenez³, Francisco Rubiño⁴, Iñigo Hernandez Rodriguez¹, Raul Menor Almagro⁵, Esther Uriarte Isacelaya⁶, Eva Tomero Muriel⁷, Tarek Carlos Salman-Monte⁸, Irene Carrion Barbera⁹, maria Galindo¹⁰, Esther Rodriguez Almaraz¹⁰, Luis Ines Sousa¹¹ and Jose M Pego-Reigosa¹², ¹Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ²Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ³IRIDIS Group, Vigo, Spain, ⁴Hospital Universitario de Jerez de la Frontera, Jerez de la frontera, Spain, ⁵Hospital Jerez de la Frontera, Cádiz, Spain, ⁶Hospital Universitario Donostia, Donostia, Spain, ⁷Hospital Universitario La Princesa, Madrid, Spain, ⁸Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, ⁹Hospital del Mar, Rheumatology, Barcelona, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal, ¹²Hospital Meixoeiro, Vigo, Spain
Background/Purpose: Treat to Target strategies are necessary in Systemic Lupus Erythematosus (SLE). They are difficult to establish due to the heterogeneity of the disease. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].